Transparency Market Research
Acute Migraine Treatment Market Predicted to Reach USD 7 billion by 2031, Recording Over a 15% CAGR Says, Transparency Market Research
August 18, 2023 06:30 ET | Transparency Market Research
Wilmington, Delaware, United States, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global market for acute migraine treatment was estimated to be worth a market valuation...
cmi_logo.png
[Latest] Global Retail Pharmacy Market Size/Share Worth USD 1,215.4 Billion by 2032 at a 7.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
August 17, 2023 11:30 ET | Custom Market Insights
Austin, TX, USA, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Retail Pharmacy Market Size, Trends and Insights By Type (Generic Medications,...
Societal Color Logo and Tagline.png
Societal CDMO Reports Second Quarter 2023 Financial Results
August 14, 2023 16:05 ET | Societal CDMO, Inc.
Recorded Q2 Revenue of $21.8 Million Signed Multiple New Business Agreements with New and Existing Customers Secured Schedule 1 Controlled Substance Manufacturing License from Drug Enforcement...
Societal Color Logo and Tagline.png
Societal CDMO Reschedules Second Quarter 2023 Financial Results Reporting to August 14, 2023
August 09, 2023 07:00 ET | Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO)...
Societal Color Logo and Tagline.png
Societal CDMO to Report Financial Results for Second Quarter 2023 on August 9, 2023
August 02, 2023 16:05 ET | Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO)...
TIP_link_300x300.jpg
4.9% CAGR for Gastrointestinal Drugs Market Size Worth $71.3Bn, Globally, by 2027 with Irritable Bowel Syndrome Segment Driving Growth During 2020-2027 | Report by The Insight Partners
July 11, 2023 10:55 ET | The Insight Partners
Pune, India, July 11, 2023 (GLOBE NEWSWIRE) -- The Insight Partners latest study on "Gastrointestinal Drugs Market Size Report, Forecast to 2027 – COVID-19 Impact and Global Analysis – by Drug...
Societal Color Logo and Tagline.png
Societal CDMO Selected by Spinnaker Biosciences to Provide CDMO Services to Support Clinical Development of Novel Therapeutic Candidate
July 10, 2023 07:00 ET | Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., July 10, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; Nasdaq: SCTL), a contract development and manufacturing organization (CDMO) dedicated to...
Full Logo - OKYO .jpg
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease
June 06, 2023 09:30 ET | OKYO Pharma LTD
Trial designed with a two-week run-in period to reduce the well-known placebo effect in trials involving pain componentTop-line data from trial anticipated in Q4, 2023 LONDON and NEW YORK, June 06,...
tiziana-logo.png
Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
May 25, 2023 07:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
PharmAla Biotech Logo 800 x 422.png
PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA
May 16, 2023 11:37 ET | PharmAla Biotech
VANCOUVER, British Columbia, May 16, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing...